- Home
- FSHP vs FATE Comparison
FSHP vs FATE Comparison
Compare FSHP & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- FATE
- Stock Information
- Founded
- FSHP 2018
- FATE 2007
- Country
- FSHP United States
- FATE United States
- Employees
- FSHP N/A
- FATE N/A
- Industry
- FSHP
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSHP
- FATE Health Care
- Exchange
- FSHP NYSE
- FATE Nasdaq
- Market Cap
- FSHP 90.7M
- FATE 108.2M
- IPO Year
- FSHP 2024
- FATE 2013
- Fundamental
- Price
- FSHP $10.33
- FATE $0.76
- Analyst Decision
- FSHP
- FATE Hold
- Analyst Count
- FSHP 0
- FATE 9
- Target Price
- FSHP N/A
- FATE $5.50
- AVG Volume (30 Days)
- FSHP 21.2K
- FATE 1.7M
- Earning Date
- FSHP 01-01-0001
- FATE 03-05-2025
- Dividend Yield
- FSHP N/A
- FATE N/A
- EPS Growth
- FSHP N/A
- FATE N/A
- EPS
- FSHP 0.17
- FATE N/A
- Revenue
- FSHP N/A
- FATE $13,631,000.00
- Revenue This Year
- FSHP N/A
- FATE N/A
- Revenue Next Year
- FSHP N/A
- FATE N/A
- P/E Ratio
- FSHP $62.54
- FATE N/A
- Revenue Growth
- FSHP N/A
- FATE N/A
- 52 Week Low
- FSHP $9.99
- FATE $0.75
- 52 Week High
- FSHP $10.35
- FATE $7.35
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- FATE 31.90
- Support Level
- FSHP N/A
- FATE $0.83
- Resistance Level
- FSHP N/A
- FATE $0.96
- Average True Range (ATR)
- FSHP 0.00
- FATE 0.06
- MACD
- FSHP 0.00
- FATE -0.00
- Stochastic Oscillator
- FSHP 0.00
- FATE 2.84
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.